GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult subjects 18 and older with chronic HCV infection
Liver biopsy results (performed no more than 3 years prior to Screening) indicating the absence of cirrhosis
Monoinfection with HCV genotype 1a or 1b
Interferon ineligible or intolerant
Body mass index (BMI) between 18 and 40 kg/m2
Use of highly effective contraception methods if female of childbearing potential or sexually active male
Screening laboratory values within defined thresholds
Has not been exposed to any investigational drug or device within 30 days of the Screening visit
Able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments
You may not be if
Prior treatment of HCV with any direct-acting antiviral (whether approved or experimental)
Decompensated liver disease or cirrhosis
Co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype
History of difficulty with blood collection and/or poor venous access
Pregnant or nursing female or male with pregnant female partner
Chronic liver disease of a non-HCV etiology
Suspicion of hepatocellular carcinoma
Clinically-relevant drug abuse
Clareo Health | GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
